Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (422) Arrow Down
Filter Results: (422) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (635)
    • People  (4)
    • News  (110)
    • Research  (422)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)

Show Results For

  • All HBS Web  (635)
    • People  (4)
    • News  (110)
    • Research  (422)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)
← Page 6 of 422 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • 14 Dec 2020
  • Research & Ideas

What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?

Pharmaceutical regulators around the world tend to speed through drug applications in December and before major national holidays, according to new research that might raise questions about COVID-19 vaccines and other treatments under... View Details
Keywords: by Danielle Kost; Pharmaceutical; Pharmaceutical
  • March 2008 (Revised June 2008)
  • Case

Sirtris Pharmaceuticals: Living Healthier, Longer

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
  • April 2010
  • Case

Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug

By: John A. Quelch and Heather Beckham
Metabical is a new weight loss drug from Cambridge Sciences Pharmaceuticals intended for moderately overweight individuals. In anticipation of final FDA approval, the senior director of marketing, Barbara Printup, prepares for the product launch and must make several... View Details
Keywords: Return On Investment; Forecasting; Pricing Policies; Demand Planning; Marketing Strategy; Price; Consumer Behavior; Investment Return; Forecasting and Prediction; Product Launch; Planning; Brands and Branding; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Quelch, John A., and Heather Beckham. "Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug." Harvard Business School Brief Case 104-183, April 2010.
  • February 1997
  • Case

Archer Daniels Midland: Direction and Strategy

By: Ray A. Goldberg and Thomas N. Urban Jr
Sets out the strategy and competitive competencies of one of the leading grain trade and processing companies in the world. An overview of the company's innovations in corn and oilseed by-products is provided. The strategy of the firm is to add by-products to corn,... View Details
Keywords: Innovation and Invention; Strategic Planning; Business Strategy; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., and Thomas N. Urban Jr. "Archer Daniels Midland: Direction and Strategy." Harvard Business School Case 597-039, February 1997.
  • April 2017
  • Supplement

Imprimis (C)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details
Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States
Citation
Purchase
Related
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (C)." Harvard Business School Supplement 717-497, April 2017.
  • October 2011 (Revised June 2013)
  • Case

Novo Nordisk: A Commitment to Sustainability

By: Robert G. Eccles and Michael P. Krzus
The case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the... View Details
Keywords: Strategic Planning; Business Ventures; Business or Company Management; Integrated Corporate Reporting; Business Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Eccles, Robert G., and Michael P. Krzus. "Novo Nordisk: A Commitment to Sustainability." Harvard Business School Case 412-053, October 2011. (Revised June 2013.)
  • January 1996
  • Case

Biogen, Inc.: rBeta Interferon Manufacturing Process Development

By: Steven C. Wheelwright
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
Keywords: Learning; Technological Innovation; Management Analysis, Tools, and Techniques; Product Development; Organizational Change and Adaptation; Projects; Research and Development; Corporate Strategy; Biotechnology Industry
Citation
Educators
Purchase
Related
Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
  • August 2013
  • Teaching Plan

Remicade-Simponi

By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson & Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Citation
Purchase
Related
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
  • March 1994 (Revised April 1994)
  • Case

Eli Lilly and Co.: The Flexible Facility Decision--1993

By: Gary P. Pisano
In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details
Keywords: Debates; Cost vs Benefits; Decisions; Investment; Goals and Objectives; Product Launch; Production; Corporate Strategy; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Pisano, Gary P. "Eli Lilly and Co.: The Flexible Facility Decision--1993." Harvard Business School Case 694-074, March 1994. (Revised April 1994.)
  • February 1996
  • Case

Chadwick, Inc.: The Balanced Scorecard (Abridged)

By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
Keywords: Balanced Scorecard; Research and Development; Product Launch; Commercialization; Consumer Behavior; Customer Focus and Relationships; Performance Evaluation; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard (Abridged)." Harvard Business School Case 196-124, February 1996.
  • January 1993 (Revised April 1993)
  • Case

Chadwick, Inc.: The Balanced Scorecard

By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
Keywords: Balanced Scorecard; Performance Evaluation; Customer Relationship Management; Goals and Objectives; Customer Satisfaction; Research and Development; Marketplace Matching; Financial Condition; Product Launch; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard." Harvard Business School Case 193-091, January 1993. (Revised April 1993.)
  • September 1990 (Revised January 1992)
  • Case

Eli Lilly and Co. (A): Globalization

By: Michael Y. Yoshino
Examines the changes taking place in Eli Lilly in response to the globalization of the pharmaceuticals industry. Identifies the steps taken by management, problems currently faced, and challenges for the future. Allows examination of the process of implementing a... View Details
Keywords: Change; Globalization; Global Strategy; Business or Company Management; Problems and Challenges; Perspective; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Yoshino, Michael Y. "Eli Lilly and Co. (A): Globalization." Harvard Business School Case 391-032, September 1990. (Revised January 1992.)
  • March 1992
  • Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details
Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
  • February 2010
  • Case

Real Blue? Viagra and Intellectual Property Rights Law in China

By: Regina M. Abrami and Tracy Manty
On July 5, 2004, Pfizer's China team received disappointing news. China's patent review board just invalidated the company's existing patent on one of its most successful drugs, Viagra. Making matters worse, a Guangdong-based pharmaceutical company laid claim to... View Details
Keywords: Trade; International Relations; Patents; Trademarks; Lawsuits and Litigation; Rights; Business and Government Relations; Pharmaceutical Industry; China
Citation
Educators
Purchase
Related
Abrami, Regina M., and Tracy Manty. "Real Blue? Viagra and Intellectual Property Rights Law in China." Harvard Business School Case 910-409, February 2010.
  • December 2017
  • Case

Charity or Bribery?

By: Eugene Soltes and Brian Tilley
Filip Kowalski, a senior manager at the pharmaceutical company Healthgen, leads sales for the firm’s Polish division. While pitching Healthgen’s products, he develops a relationship with a director of a regional health fund who also runs a private foundation. After a... View Details
Keywords: Bribery; Crime and Corruption; Law; Ethics; Philanthropy and Charitable Giving; United States; Europe
Citation
Educators
Purchase
Related
Soltes, Eugene, and Brian Tilley. "Charity or Bribery?" Harvard Business School Case 118-052, December 2017.
  • March 2008 (Revised March 2022)
  • Case

Cadbury Schweppes: Capturing Confectionery (A)

By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Keywords: Business History; Strategy; Decision Choices and Conditions; Mergers and Acquisitions; Food and Beverage Industry
Citation
Educators
Purchase
Related
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (A)." Harvard Business School Case 708-453, March 2008. (Revised March 2022.)
  • Research Summary

AIDS in Africa: Life, Death and Property Rights

By: Debora L. Spar
In the final years of the twentieth century, the world was hit by a plague of epidemic proportions--the plague of AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought... View Details
  • January 2023 (Revised August 2023)
  • Case

Veeva Systems and the Transformation to a Public Benefit Corporation

By: Ranjay Gulati and Allison M. Ciechanover
Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the... View Details
Keywords: Transformation; Corporate Governance; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Culture; Information Technology Industry; Technology Industry; United States; California
Citation
Educators
Purchase
Related
Gulati, Ranjay, and Allison M. Ciechanover. "Veeva Systems and the Transformation to a Public Benefit Corporation." Harvard Business School Case 423-045, January 2023. (Revised August 2023.)
  • September 1993
  • Case

Manufacturing at ALZA: The Right Prescription? (A)

By: Dorothy A. Leonard
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
Keywords: Business or Company Management; Technological Innovation; Innovation and Management; Growth and Development Strategy; Problems and Challenges; Production; Research and Development; Organizational Change and Adaptation; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Find at Harvard
Related
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
  • 23 Mar 2003
  • Research & Ideas

AIDS in Africa—What’s the Solution?

according to panelists from the healthcare field and the pharmaceutical industry, is delivering drugs that are donated or available at reduced prices to patients who need them. Government Priorities Dr. Konji Sebati, a physician with the... View Details
Keywords: by Julie Jette
  • ←
  • 6
  • 7
  • …
  • 21
  • 22
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.